Together with our Novasome Research and Development Centre, we received a subsidy that will help us carry out an urgent and important project – developing a product for the treatment of type 2 diabetes

and conducting the clinical trials required to obtain a marketing authorisation.

The product we will develop is a response to the needs of the national and European pharmaceutical market and is in line with the pharmaceutical strategy for Europe and the move towards strengthening health protection systems in anticipation of crises.

We are more than happy that the grant we received will allow us to create a drug that will help patients!